Key Points
Oryzon Genomics ORY.MC rises 0.43% on positive iadademstat clinical data.
Iadademstat achieves 100% overall response rate and 93% complete remission in AML trials.
Company maintains €0.37 cash per share with 1.95 current ratio for funding operations.
Meyka AI rates ORY.MC with C+ grade suggesting Hold amid clinical-stage development risks.
Oryzon Genomics S.A. (ORY.MC) gained 0.43% on EURONEXT today, trading at €2.772 as the Spanish biotech company released encouraging clinical trial results. The company presented updated positive data for iadademstat (ORY-1001), its lead LSD1 inhibitor candidate, showing a 100% overall response rate in acute myeloid leukemia patients. The first-line combination therapy achieved a composite complete remission rate of 93%, with an estimated 12-month overall survival of 74%. This milestone comes ahead of the European Hematology Association conference, reinforcing investor confidence in Oryzon’s oncology pipeline despite the company’s pre-revenue stage and ongoing clinical development phase.
Iadademstat Clinical Breakthrough Drives ORY.MC Stock Momentum
Oryzon’s iadademstat demonstrated remarkable efficacy in combination with azacitidine and venetoclax for first-line acute myeloid leukemia treatment. The 100% overall response rate represents a significant clinical achievement, with 93% composite complete remission and 79% complete remission rates. The estimated 12-month overall survival of 74% positions iadademstat favorably against existing treatment standards.
In the FLT3-mutated refractory-relapsed setting, iadademstat combined with gilteritinib showed a 67% composite complete remission rate with a favorable safety profile. These results validate Oryzon’s epigenetics-based therapeutic approach and strengthen the company’s competitive position in the oncology market. Track ORY.MC on Meyka for real-time updates on clinical trial announcements and regulatory milestones.
ORY.MC Stock Valuation and Market Position
Oryzon Genomics trades at a market capitalization of €217 million with 78.9 million shares outstanding. The stock’s current price of €2.772 reflects a year-to-date decline of 11.51%, though it remains above the 52-week low of €2.555. The company’s 52-week high of €4.02 demonstrates significant volatility typical of clinical-stage biotech firms.
Meyka AI rates ORY.MC with a grade of C+, suggesting a Hold recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company carries a negative EPS of -€0.03 and trades at a negative PE ratio of -91.73, reflecting its pre-revenue status. These grades are not guaranteed and we are not financial advisors.
Financial Health and Cash Position
Oryzon maintains a current ratio of 1.95, indicating adequate short-term liquidity to fund operations and clinical trials. The company holds €0.37 cash per share, providing runway for ongoing development of iadademstat and vafidemstat (ORY-2001), its CNS-optimized LSD1 inhibitor candidate.
The biotech firm operates with a debt-to-equity ratio of 0.11, demonstrating conservative leverage. Working capital stands at €14.9 million, supporting the company’s 470-employee workforce based in Cornellà de Llobregat, Spain. Operating cash flow remains negative, typical for clinical-stage companies investing heavily in R&D and regulatory pathways.
Market Sentiment and Technical Outlook
Trading Activity: ORY.MC recorded 43,245 shares in today’s session, significantly below the 330,839-share average volume, indicating subdued retail participation despite positive clinical news. The relative volume of 0.39 suggests institutional investors may be awaiting additional data before increasing positions.
Liquidation: The stock’s RSI of 44.70 indicates neutral momentum, neither overbought nor oversold. The MACD histogram at 0.00 with matching signal lines suggests a potential trend inflection point. Bollinger Bands show the stock trading near the middle band at €2.80, with upper resistance at €2.89 and support at €2.71. The Money Flow Index at 29.10 signals weak buying pressure, typical of early-stage clinical announcements requiring time for market digestion.
Final Thoughts
Oryzon Genomics’ positive iadademstat clinical data represents a meaningful catalyst for ORY.MC stock, though the modest 0.43% gain reflects cautious market sentiment toward clinical-stage biotech. The 100% overall response rate and 93% composite complete remission in first-line AML treatment validate the company’s epigenetics platform and support continued development. However, investors should recognize that clinical success does not guarantee regulatory approval or commercialization. The company’s negative earnings, limited cash runway, and reliance on trial outcomes create inherent risks. Meyka AI’s AI-powered market analysis platform tracks real-time developments in biote…
FAQs
Iadademstat (ORY-1001) is a selective LSD1 inhibitor for cancer and CNS disorders. It inhibits lysine-specific demethylase 1, an epigenetic enzyme regulating gene expression, and is currently in Phase II trials for acute myeloid leukemia.
Clinical-stage biotech stocks often show muted reactions to trial results due to regulatory uncertainty. Low trading volume also limited price movement. Investors typically await Phase III data before significant revaluation.
Oryzon maintains €0.37 cash per share and a 1.95 current ratio, indicating adequate near-term liquidity. As a pre-revenue company, additional funding through partnerships, grants, or capital raises will likely be required.
The C+ grade with Hold recommendation reflects mixed fundamentals: strong clinical potential offset by negative earnings, limited revenue, and high development risk. It is not a buy or sell recommendation.
Iadademstat is in Phase II trials without regulatory approval. The typical biotech timeline requires Phase III trials, regulatory submissions, and FDA/EMA review—typically 3-5 years from the current stage.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)